



Report Cover Sheet

Report to:	Trust Board	
Date of the Meeting:	25 March 2020	
Agenda Item:	P1-049-20 a	
Title:	Proton Service – Communication with Stakeholders Update	
Report prepared by:	Angela Wendzicha	
Executive Lead:	Liz Bishop	
Status of the Report:	Public	Private
	X	

Paper previously considered by:	Not applicable
Date & Decision:	Not applicable

Purpose of the Paper/Key Points for Discussion:	<p>The Board will recall that all external communication concerning the Proton service was and continues to be led by NHS England.</p> <p>Following approval from NHS England, we have recently circulated the attached letter to the five ocular oncology centres in the UK.</p>
---	---

Action Required:	Discuss	
	Approve	
	For Information/Noting	X

Next steps required	Not applicable
---------------------	----------------

The paper links to the following strategic priorities (please tick)

Deliver outstanding care locally	√	Collaborative system leadership to deliver better patient care	√
Retain and develop outstanding staff		Be enterprising	
Invest in research & innovation to deliver excellent patient care in the future	√	Maintain excellent quality, operational and financial performance	

The paper relates to the following Board Assurance Framework (BAF) Risks

BAF Risk	Please Tick
1. If we do not optimise quality outcomes we will not be able to provide outstanding care	
2. If we do not prioritise the costs of the delivering the Transforming Cancer Care Programme we will not be able to maintain our long-term financial strength and make appropriate strategic investments.	
3. If we do not have the right infrastructure (estate, communication & engagement, information and technology) we will be unable to deliver care close to home.	√
4. If we do not have the right innovative workforce solutions including education and development, we will not have the right skills, in the right place, at the right time to deliver the outstanding care.	
5. If we do not have an organisational culture that promotes positive staff engagement and excellent health and well-being we will not be able to retain and attract the right workforce.	
6. If we fail to implement and optimise digital technology we will not deliver optimal patient outcomes and operational effectiveness.	
7. If we fail to position the organisation as a credible research partner we will limit patient access to clinical trials and affect our reputation as a specialist centre delivering excellent patient care in the future.	
8. If we do not retain system-side leadership, for example, SRO for Cancer Alliance and influence the National Cancer Policy, we will not have the right influence on the strategic direction to deliver outstanding cancer services for the population of Cheshire & Merseyside.	
9. If we do not support and invest in entrepreneurial ideas and adapt to changes in national priorities and market conditions we will stifle innovative cancer services for the future.	
10. If we do not continually support, lead and prioritise improved quality, operational and financial performance, we will not provide safe, efficient and effective cancer services.	√

Equality & Diversity Impact Assessment		
Are there concerns that the policy/service could have an adverse impact on:	YES	NO
Age		X
Disability		X
Gender		X
Race		X
Sexual Orientation		X
Gender Reassignment		X
Religion/Belief		X
Pregnancy and Maternity		X

If YES to one or more of the above please add further detail and identify if a full impact assessment is required.



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Our Ref: LB/001/ZM

To: [REDACTED]

via email: [REDACTED]

2 March 2020

Dear [REDACTED]

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Proton Service for the Treatment of Ocular Cancer

The Clatterbridge Cancer Centre and NHS England remain committed to the ongoing provision of the national low-energy proton service for the treatment of ocular cancer.

The Clatterbridge Cancer Centre has long pioneered this service, which is unique in the UK and which uses a low-energy proton beam to provide targeted treatment for tumors' in the eye.

As the current equipment is coming to the end of its lifespan, we have been in discussions with the NHS England Highly Specialised Commissioning Team. These discussions have been positive and we have now agreed a way forward which involves an enhanced engineering service and refurbishment of the current equipment*.

We will continue to work in partnership with NHS England to develop an intermediate solution. It is difficult to be precise about this but the specialist advice along with the upgrades means we think we can keep the instrument viable for up to 3-5 years. During this period we will also work with NHSE and the wider ocular oncology community to develop a long-term plan for the treatment of ocular cancer.

During this period, The Clatterbridge Cancer Centre will continue to provide low-energy proton beam therapy for patients with ocular cancers. Please continue to refer patients to the service in the usual way.

Chief Executive

Tel: 0151 556 5011

Mobile: 07808 964045

*Note: We are not anticipating any break in service while this engineering work takes place. We will inform you in advance if we need to carry out significant work in the future that means the equipment will be unavailable for a short time.